Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Current Deferred Revenue (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Current Deferred Revenue for 4 consecutive years, with $168000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Deferred Revenue changed N/A year-over-year to $168000.0, compared with a TTM value of $168000.0 through Sep 2025, changed N/A, and an annual FY2024 reading of $151000.0, down 88.46% over the prior year.
  • Current Deferred Revenue was $168000.0 for Q3 2025 at Aligos Therapeutics, down from $579000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $7.6 million in Q1 2021 and bottomed at $151000.0 in Q4 2024.
  • Average Current Deferred Revenue over 4 years is $3.3 million, with a median of $1.3 million recorded in 2023.
  • Peak annual rise in Current Deferred Revenue hit 88.46% in 2024, while the deepest fall reached 88.46% in 2024.
  • Year by year, Current Deferred Revenue stood at $6.6 million in 2021, then plummeted by 80.29% to $1.3 million in 2023, then tumbled by 88.46% to $151000.0 in 2024, then grew by 11.26% to $168000.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for ALGS at $168000.0 in Q3 2025, $579000.0 in Q2 2025, and $151000.0 in Q4 2024.